WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for REGN

Based on 24 analysts offering 12 month price targets for Regeneron Pharmaceuticals Inc

Min Forecast
$185.00-80.75%
Avg Forecast
$904.29-5.93%
Max Forecast
$1,175.00+22.24%

Should I buy or sell REGN stock?

Based on 24 analysts offering ratings for Regeneron Pharmaceuticals Inc.

Strong Buy
Strong Buy
14 analysts 58.33%
Buy
2 analysts 8.33%
Hold
8 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their REGN stock forecasts and price targets.

REGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-02
lockedlocked$00.00+00.00%2026-11-02
lockedlocked$00.00+00.00%2026-11-02
lockedlocked$00.00+00.00%2026-11-02
lockedlocked$00.00+00.00%2026-11-02
Guggenheim
Top 3%
98
Strong BuyMaintains$1,100.00+14.43%2026-11-02
Wells Fargo
Top 11%
90
HoldMaintains$925.00-3.77%2026-11-02
Evercore ISI Group
Top 17%
84
BuyMaintains$1,075.00+11.83%2026-11-02
Canaccord Genuity
Bottom 3%
3
Strong BuyMaintains$1,175.00+22.24%2026-11-02
Cantor Fitzgerald
Top 8%
93
Strong BuyMaintains$980.00+1.95%2026-11-02

1 of 3

Forecast return on equity

Is REGN forecast to generate an efficient return?

Company
22.88%
Industry
20.61%
Market
175.47%
REGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is REGN forecast to generate an efficient return on assets?

Company
17.26%
Industry
21.67%
REGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

REGN earnings per share forecast

What is REGN's earnings per share in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$64.35+36.89%
Avg 2 year Forecast
$69.87+48.63%
Avg 3 year Forecast
$75.44+60.48%
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

REGN revenue forecast

What is REGN's revenue in the next 3 years based on estimates from 31 analysts?

Avg 1 year Forecast
$18.7B+10.43%
Avg 2 year Forecast
$20.1B+19.19%
Avg 3 year Forecast
$21.5B+27.25%
REGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

REGN earnings growth forecast

How is REGN forecast to perform vs Biotechnology companies and vs the US market?

Company
17.07%
Industry
11.85%
Market
32.68%
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

REGN revenue growth forecast

How is REGN forecast to perform vs Biotechnology companies and vs the US market?

Company
8.4%
Industry
29.73%
Market
12.59%
REGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
REGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

REGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REGN$961.26$904.29-5.93%Strong Buy
MRNA$220.83$101.21-54.17%Hold
VRTX$553.15$555.18+0.37%Strong Buy
ARGX$874.97$1,151.38+31.59%Strong Buy
ONC$361.27$421.36+16.63%Strong Buy
View Top Biotech Stocks

Regeneron Pharmaceuticals Stock Forecast FAQ

Is Regeneron Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 24 Wall Street analysts covering (NASDAQ: REGN) stock is to Strong Buy REGN stock.

Out of 24 analysts, 14 (58.33%) are recommending REGN as a Strong Buy, 2 (8.33%) are recommending REGN as a Buy, 8 (33.33%) are recommending REGN as a Hold, 0 (0%) are recommending REGN as a Sell, and 0 (0%) are recommending REGN as a Strong Sell.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

What is REGN's earnings growth forecast for 2026-2028?

(NASDAQ: REGN) Regeneron Pharmaceuticals's forecast annual earnings growth rate of 17.07% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.

Regeneron Pharmaceuticals's earnings in 2026 is $4,817,400,000.On average, 32 Wall Street analysts forecast REGN's earnings for 2026 to be $6,656,962,830, with the lowest REGN earnings forecast at $5,257,406,401, and the highest REGN earnings forecast at $7,783,727,255. On average, 31 Wall Street analysts forecast REGN's earnings for 2027 to be $7,228,232,941, with the lowest REGN earnings forecast at $4,276,875,869, and the highest REGN earnings forecast at $9,007,225,773.

In 2028, REGN is forecast to generate $7,804,220,276 in earnings, with the lowest earnings forecast at $4,778,897,984 and the highest earnings forecast at $9,556,409,767.

What is REGN's revenue growth forecast for 2026-2028?

(NASDAQ: REGN) Regeneron Pharmaceuticals's forecast annual revenue growth rate of 8.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.59%.

Regeneron Pharmaceuticals's revenue in 2026 is $16,896,200,000.On average, 31 Wall Street analysts forecast REGN's revenue for 2026 to be $1,930,233,601,081, with the lowest REGN revenue forecast at $1,695,200,065,433, and the highest REGN revenue forecast at $2,116,646,642,999. On average, 30 Wall Street analysts forecast REGN's revenue for 2027 to be $2,083,336,432,401, with the lowest REGN revenue forecast at $1,754,682,584,358, and the highest REGN revenue forecast at $2,353,128,448,673.

In 2028, REGN is forecast to generate $2,224,128,968,500 in revenue, with the lowest revenue forecast at $1,867,026,959,232 and the highest revenue forecast at $2,611,954,991,891.

What is REGN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: REGN) forecast ROA is 17.26%, which is lower than the forecast US Biotechnology industry average of 21.67%.

What is REGN's Price Target?

According to 24 Wall Street analysts that have issued a 1 year REGN price target, the average REGN price target is $904.29, with the highest REGN stock price forecast at $1,175.00 and the lowest REGN stock price forecast at $185.00.

On average, Wall Street analysts predict that Regeneron Pharmaceuticals's share price could fall to $904.29 by Nov 2, 2027. The average Regeneron Pharmaceuticals stock price prediction forecasts a potential downside of 5.93% from the current REGN share price of $961.26.

What is REGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: REGN) Regeneron Pharmaceuticals's current Earnings Per Share (EPS) is $47.01. On average, analysts forecast that REGN's EPS will be $64.35 for 2026, with the lowest EPS forecast at $50.82, and the highest EPS forecast at $75.24. On average, analysts forecast that REGN's EPS will be $69.87 for 2027, with the lowest EPS forecast at $41.34, and the highest EPS forecast at $87.07. In 2028, REGN's EPS is forecast to hit $75.44 (min: $46.20, max: $92.38).

What is REGN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: REGN) forecast ROE is 22.88%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.